49 results
424B3
BIAF
BioAffinity Technologies Inc
16 Apr 24
Prospectus supplement
7:19pm
test’s ability to assist physicians with next steps in patient care. In January 2024, we began using the new marketing materials with both physicians … in the future require licenses to third-party technology and materials. We had previously been granted a license from Village Oaks to use its intellectual
DEFA14A
BIAF
BioAffinity Technologies Inc
15 Apr 24
Additional proxy soliciting materials
6:17am
))
Definitive Proxy Statement
Definitive Additional Materials
Soliciting Material Pursuant to §240.14a-12
bioAffinity Technologies, Inc.
(Exact Name … the appropriate box):
No fee required.
Fee paid previously with preliminary materials.
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11.
POS AM
bz3xnlfj5fm78uq
1 Apr 24
Prospectus update (post-effective amendment)
8:06pm
8-K
EX-99.1
46gw8 1rz
1 Apr 24
Results of Operations and Financial Condition
4:00pm
D
ar3v vkqs4va8ypgp
20 Mar 24
$2.62 mm in equity / options / securities to be acquired, sold $2.62 mm, 3 investors
2:24pm
8-K
EX-1.1
qmrw2p63ivm 0s4wnj45
8 Mar 24
Entry into a Material Definitive Agreement
5:00pm
8-K
EX-10.1
kdi3q8d bo1y
8 Mar 24
Entry into a Material Definitive Agreement
5:00pm
424B5
vsn1zza699tnv7vp3yyc
8 Mar 24
Prospectus supplement for primary offering
12:18pm
424B5
dcmefx
7 Mar 24
Prospectus supplement for primary offering
9:57pm
8-K
EX-10.1
yrbaant6nlgi99g5h
5 Dec 23
Departure of Directors or Certain Officers
8:45am
424B5
y4he2htaatxkq
28 Nov 23
Prospectus supplement for primary offering
4:00pm
S-3
nrqcf9hoo it
16 Nov 23
Shelf registration
5:23pm
S-3
EX-4.3
qyj8s
16 Nov 23
Shelf registration
5:23pm